Abstract 371P
Background
Head and neck cancers (HNCs) are a challenging disease to treat due to their anatomical complexity and high propensity for locoregional recurrence. Radiation therapy is a crucial component of treatment approach for HNCs. However, assessing the response to therapy can be difficult, particularly in the early post-treatment period. Positron emission tomography (PET) with the glucose analogue [18F] fluorodeoxyglucose (FDG) has shown promising results in the assessment of treatment response in HNCs. Therefore, this systematic review is written to evaluate the role of FDG-PET/CT in the assessment of response to radiotherapy in HNCs.
Methods
A comprehensive search of electronic databases was conducted, including EMBASE, Scopus, Pubmed, PMC, and Science Direct from inception to April 2023. Studies were included if they reported on the use of FDG-PET/CT for assessing treatment response in HNCs treated with radiation therapy. Quality assessment using Newcastle-Ottawa Scale and data extraction were performed independently by three reviewers.
Results
16 studies reporting on a total of 348 patients were included in this analysis. The data assessed in the included studies were diverse, including the evaluation of the diagnostic performance of FDG-PET/CT, the comparison with conventional imaging techniques, the ability to avoid neck dissections, or assessed which patient population would derive most benefit from post-treatment FDG-PET/CT scan. Despite their diversity, almost all studies have showed that FDG-PET/CT scan is a reliable method to evaluate residual or recurrent tumour within 6 months post-(chemo)radiation therapy with pooled sensitivity of 84% and pooled specificity of 90%. There was a moderate risk of bias due to selection bias. Also, confirmation of positive nodal disease at the time of diagnosis and prior to therapy is an important shortcoming in most included studies.
Conclusions
FDG-PET/CT within 6 months after (chemo)radiotherapy in HNCs patients is a reliable method for ruling out residual/recurrent nodal disease and obviates the need for therapeutic intervention. However, further standardization of the PET technique is required.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
352TiP - Randomized phase III study of daratumumab (D) versus bortezomib plus D as a maintenance therapy after D-MPB for elderly or non-elderly patients refusing transplant with untreated multiple myeloma (JCOG1911, B-DASH study)
Presenter: Tomotaka Suzuki
Session: Poster Display
Resources:
Abstract
362P - Efficacy and safety of MCLA-129, an anti-EGFR/c-MET bispecific antibody, in head and neck squamous cell cancer (HNSCC)
Presenter: Irene Braña
Session: Poster Display
Resources:
Abstract
363P - Effect of financial distress and mental well-being of patients with early vs advanced oral cancer on informal caregiver's quality of life: A prospective real-world data from public health sector hospital
Presenter: Abhinav Thaduri
Session: Poster Display
Resources:
Abstract
364P - Artificial intelligence provides more accurately neck lymph nodes auto-segmentation in radiotherapy
Presenter: chiencheh Chen
Session: Poster Display
Resources:
Abstract
365P - Radiotherapy treatment outcomes and treatment compliance of nasopharyngeal cancer patients in Sabah: A retrospective analysis
Presenter: Anbarasan Anbazagan
Session: Poster Display
Resources:
Abstract
366P - Pre-treatment oral fungal microbiome and nasopharyngeal carcinoma prognosis: A population-based cohort study in southern China
Presenter: Yufeng Chen
Session: Poster Display
Resources:
Abstract
367P - Prevalence and association of sarcopenia with mortality in patients with head and neck cancer: A meta-analysis
Presenter: Claire Lim
Session: Poster Display
Resources:
Abstract
368P - Distinct gene expression profiling explored using nanostring tumor signalling 360 panel with validations in different clinical stages of oral submucous fibrosis patients: A first Indian study
Presenter: Yasasve Madhavan
Session: Poster Display
Resources:
Abstract
370P - Low-dose nivolumab with induction chemotherapy for inoperable HNSCC in 111 patients: Response rates, survival, and implications for LMICs
Presenter: Josh Thomas Georgy
Session: Poster Display
Resources:
Abstract
372P - Effectiveness of HAN-MI-RADS (head and neck molecular imaging-reporting and data system) criterion in head and neck squamous cell carcinoma post concurrent chemoradiotherapy
Presenter: Manoj Gupta
Session: Poster Display
Resources:
Abstract